Galgiani J N, Stevens D A, Graybill J R, Stevens D L, Tillinghast A J, Levine H B
Chest. 1984 Aug;86(2):219-24. doi: 10.1378/chest.86.2.219.
Seven patients infected with Pseudallescheria boydii were treated with oral ketoconazole, 200 to 600 mg/day for one to 13 months. Five patients had pulmonary infections; two had skeletal infections. Improvement of pretreatment abnormalities occurred in five patients, one of whom had concurrent arthrodesis of his infected knee. The other two patients were subsequently healed by surgical resection of their pulmonary lesions. Ketoconazole appeared less active than miconazole against 22 clinical isolates of P boydii when tested by two in vitro methods. We conclude that ketoconazole is effective treatment for some patients infected with P boydii, although this may not be predicted by current in vitro susceptibility tests. Further experience is needed to establish the optimal use of ketoconazole with respect to its dosage, duration of administration and concurrent surgical resection.
7例波氏假阿利什霉感染患者接受口服酮康唑治疗，剂量为每日200至600毫克，疗程1至13个月。5例患者发生肺部感染；2例患者发生骨骼感染。5例患者治疗前的异常情况有所改善，其中1例患者同时接受了感染膝关节的关节固定术。另外2例患者随后通过手术切除肺部病变而治愈。当采用两种体外方法进行检测时，酮康唑对22株临床分离的波氏假阿利什霉的活性似乎低于咪康唑。我们得出结论，酮康唑对一些波氏假阿利什霉感染患者有效，尽管目前的体外药敏试验可能无法预测这一点。需要进一步积累经验，以确定酮康唑在剂量、给药持续时间和同期手术切除方面的最佳使用方法。
